Fig. 5

Plasma NfL better predicts survival after symptom onset than plasma GFAP. Comparisons of baseline GFAP (a, b) or NfL (c, d) concentrations in predicting survival after symptom onset in participants with bvFTD or in the combined group of participants with a FTD syndrome. For ease of presentation, GFAP and NfL were divided into a 2-level categorical variable based on sample medians. bvFTD, n = 301 (participants who died, n = 42); all FTD syndromes, n = 678 (participants who died, n = 105). In (a): Low ≤ 247.00 pg/ml, High > 247.00 pg/ml. In (b): Low ≤ 237.00 pg/ml, High > 237.00 pg/ml. In (c): Low ≤ 42.00 pg/ml, High > 42.00 pg/ml. In (d) Low ≤ 32.00 pg/ml, High > 32.00 pg/ml. See also Table S26